Regeneron Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$803.90(as of Sep 22, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Regeneron Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$803.90
Ticker SymbolREGN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees15,410
CountyUSA
Market Cap$82,175.6M
EBIDTA4,702.4M
10-Day Moving Average790.12
P/E Ratio19.83
20-Day Moving Average805.40
Forward P/E Ratio14.20
50-Day Moving Average768.63
Earnings per Share40.42
200-Day Moving Average732.86
Profit Margin30.23%
RSI53.88
Shares Outstanding101.1M
ATR19.16
52-Week High859.34
Volume599,117
52-Week Low538.24
Most Recent Support Level769.57
Book Value31,711.0M
Most Recent Resistance Level859.34
P/B Ratio2.71
Upper Keltner848.51
P/S Ratio5.53
Lower Keltner762.28
Debt-to-Equity Ratio0.06
Next Earnings Date10/27/2026
Cash Surplus-3,074.8M
Next Ex-Dividend DateUnknown

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.